Two new glucose sensors (IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)) will be investigated to determine the optimal calibration method in patients with type 1 diabetes

The subjects (Type 1 diabetes) will stay at the Clinical Research Centre for the whole period of the investigation (12 hours).

Continuous blood glucose monitoring will be performed using the IR-Glucose Reader system and/or the IR-CGM system based on microdialysis. In parallel blood glucose measurements will be performed every 15 min as reference. The measurements of the sensors will be calibrated with different schemes and the difference between the calibrated glucose readings and the reference blood glucose values will be determined.

Inclusion Criteria:

• Informed consent obtained after being advised of the nature of the study
• Male or female aged 18 to 75 years (both inclusive)
• The subject has Type 1 diabetes (as defined by WHO) for at least 24 months
• Body Mass Index (BMI) <= 35 kg/m2

Exclusion Criteria:

• Subject is actively enrolled in another clinical trial or took part in a study within 30 days
• Experienced recurrent severe hypoglycaemic unawareness (as judged by the investigator)
• A history of drug or alcohol dependence
• Positive result for HIV antibodies
• Positive result for Hepatitis B antigen or Hepatitis C antibodies
• Any other significant concomitant disease such as endocrine, cardiac, neurological, malignant, other pancreatic disease or uncontrolled hypertension as judged by the investigator
• Patient is pregnant, or breast feeding during the period of the study
• Patient donated blood in the last 3 months